Business
CSL to manufacture 81m COVID-19 vaccine doses by mid-2021 – The Australian Financial Review
CSL has secured agreements with AstraZeneca to produce 30 million doses of its vaccine candidate locally if the drug is successful.
The two deals are expected to cost the government more than $1.7 billion, if the vaccines become available.
At this stage the AstraZeneca vaccine is more advanced and is considered the leading candidate globally, with phase-three clinical trials already starting. The first doses are scheduled for release early next year. The UQ vaccine is expected to be ready a short time later in mid-2021.
CSL chief scientific officer Dr Andrew Nash was optimistic about the potential for a vaccine in early 2…
-
Noosa News24 hours agoHomicide investigation launched into stabbing death of 39-year-old Brisbane man at Bowen Hills apartment
-
General22 hours agoSector warns Coalition’s plan to limit overseas students ‘straight out of Trump’s playbook’
-
General15 hours agoFrench far-right supporters rally against Le Pen conviction in Paris
-
General22 hours agoFire razes Tumby Bay hardware store with damage likely to exceed $1m